Through SeerPharma’s partnership with the University of Technology Sydney (UTS) and the Master of Good Manufacturing Practice (GMP) program, our focus is on developing graduates who can enter regulated industries with a strong foundation, adapt quickly to professional roles, and begin adding value sooner.
Interested in pursuing Postgraduate GMP qualifications in 2027? Applications to join our next cohort in March 2027 close soon?
SeerPharma and the University of Technology Sydney (UTS) invite you to an informative careers session exploring opportunities across the pharmaceutical, biotechnology, medical device and broader life sciences industries.
Paper logbooks are still everywhere on GMP manufacturing floors. They do the job, but they cost more than most sites realise.
Artificial intelligence is rapidly becoming part of everyday quality and regulatory activities. It can help draft procedures and specifications, generate risk management documentation, and create quality records. The numerous AI tools available can significantly improve efficiency.
Training has always been important in regulated industries, especially for those involved in the manufacture and handling of pharmaceuticals, medical devices and healthcare products.
Artificial Intelligence is rapidly transforming the life sciences industry. But how can organisations harness its potential while maintaining the quality, compliance and control expected within a regulated GxP environment?
Artificial intelligence is becoming ubiquitous, with organisations using it to improve productivity, analyse information faster, support decision-making, and find new ways of working.
In the medical device industry, internal audits are often viewed primarily as a regulatory requirement. ISO 13485:2016 requires organisations to assess the effectiveness of their Quality Management System (QMS). However, organisations that treat internal auditing purely as a compliance exercise risk missing a significant opportunity.
Copyright © SeerPharma
